Row

A. Giza challenge, AnhuiVACC

3.51 AU to center | GMT: 9 | 27 detectable titers

B. Giza challenge, AC-AnhuiVACC

2.27 AU to center | GMT: 27 | 69 detectable titers

C. Giza challenge, GizaVACC

2.78 AU to center | GMT: 16 | 48 detectable titers

Row

D. Sichuan challenge, AnhuiVACC

3.60 AU to center | GMT: 6 | 7 detectable titers

E. Sichuan challenge, AC-AnhuiVACC

1.73 AU to center | GMT: 10 | 38 detectable titers

F. Sichuan challenge, SichuanVACC

4.23 AU to center | GMT: 7 | 21 detectable titers

Row

Data S8. Merged antibody profiles of upon vaccination with split-inactivated vaccines containing wild-type HA antigens or the antigenically central HA antigen. An interactive version of the antibody profiles displayed in Fig. 3. For each group, the position, breadth and height of a mean merged serum per group (n=6) are represented in the antigenic map from Fig. 1B. (A-C) Immune responses upon vaccination with A(H5N6) split-inactivated vaccines in the Giza challenge study or (D-F) A(H5N1) split-inactivated vaccines in the Sichuan challenge study. HA antigen present in vaccine: (A, D) AnhuiVACC, (B, E) AC-AnhuiVACC, (C) GizaVACC, and (F) SichuanVACC. Using the same representation as Data S6. GMT: geometric mean titer.